|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SBNO2 |
Gene summary for SBNO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SBNO2 | Gene ID | 22904 |
| Gene name | strawberry notch homolog 2 | |
| Gene Alias | KIAA0963 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000768 | UniProtAcc | Q9Y2G9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22904 | SBNO2 | LZE5T | Human | Esophagus | ESCC | 1.06e-03 | 1.55e-01 | 0.0514 |
| 22904 | SBNO2 | LZE8T | Human | Esophagus | ESCC | 1.82e-04 | 1.72e-01 | 0.067 |
| 22904 | SBNO2 | LZE24T | Human | Esophagus | ESCC | 1.53e-04 | 2.48e-02 | 0.0596 |
| 22904 | SBNO2 | LZE21T | Human | Esophagus | ESCC | 5.08e-04 | 1.75e-01 | 0.0655 |
| 22904 | SBNO2 | P2T-E | Human | Esophagus | ESCC | 1.45e-10 | 2.33e-02 | 0.1177 |
| 22904 | SBNO2 | P4T-E | Human | Esophagus | ESCC | 4.95e-08 | 3.84e-02 | 0.1323 |
| 22904 | SBNO2 | P5T-E | Human | Esophagus | ESCC | 4.99e-04 | 4.39e-02 | 0.1327 |
| 22904 | SBNO2 | P8T-E | Human | Esophagus | ESCC | 4.37e-09 | 2.31e-01 | 0.0889 |
| 22904 | SBNO2 | P9T-E | Human | Esophagus | ESCC | 5.57e-05 | 1.09e-01 | 0.1131 |
| 22904 | SBNO2 | P10T-E | Human | Esophagus | ESCC | 5.24e-09 | 9.91e-02 | 0.116 |
| 22904 | SBNO2 | P11T-E | Human | Esophagus | ESCC | 1.93e-04 | 2.64e-01 | 0.1426 |
| 22904 | SBNO2 | P15T-E | Human | Esophagus | ESCC | 2.13e-03 | 5.01e-02 | 0.1149 |
| 22904 | SBNO2 | P16T-E | Human | Esophagus | ESCC | 5.78e-05 | 4.03e-02 | 0.1153 |
| 22904 | SBNO2 | P17T-E | Human | Esophagus | ESCC | 1.25e-03 | 2.05e-01 | 0.1278 |
| 22904 | SBNO2 | P20T-E | Human | Esophagus | ESCC | 3.24e-09 | 6.52e-02 | 0.1124 |
| 22904 | SBNO2 | P21T-E | Human | Esophagus | ESCC | 1.63e-15 | 1.77e-01 | 0.1617 |
| 22904 | SBNO2 | P22T-E | Human | Esophagus | ESCC | 2.71e-09 | -2.68e-02 | 0.1236 |
| 22904 | SBNO2 | P23T-E | Human | Esophagus | ESCC | 2.15e-06 | 3.13e-01 | 0.108 |
| 22904 | SBNO2 | P24T-E | Human | Esophagus | ESCC | 5.75e-08 | 1.66e-01 | 0.1287 |
| 22904 | SBNO2 | P26T-E | Human | Esophagus | ESCC | 1.80e-05 | -1.49e-02 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:199082316 | Esophagus | ESCC | response to leukemia inhibitory factor | 60/8552 | 95/18723 | 4.41e-04 | 2.48e-03 | 60 |
| GO:199083015 | Esophagus | ESCC | cellular response to leukemia inhibitory factor | 59/8552 | 94/18723 | 6.19e-04 | 3.32e-03 | 59 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
| GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
| GO:00303165 | Esophagus | ESCC | osteoclast differentiation | 54/8552 | 94/18723 | 1.43e-02 | 4.65e-02 | 54 |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
| GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
| GO:00712226 | Liver | HCC | cellular response to lipopolysaccharide | 110/7958 | 209/18723 | 1.92e-03 | 9.77e-03 | 110 |
| GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
| GO:00712196 | Liver | HCC | cellular response to molecule of bacterial origin | 113/7958 | 221/18723 | 5.73e-03 | 2.38e-02 | 113 |
| GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
| GO:000257310 | Oral cavity | OSCC | myeloid leukocyte differentiation | 119/7305 | 208/18723 | 7.29e-08 | 1.29e-06 | 119 |
| GO:003249617 | Oral cavity | OSCC | response to lipopolysaccharide | 178/7305 | 343/18723 | 7.27e-07 | 1.03e-05 | 178 |
| GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SBNO2 | SNV | Missense_Mutation | novel | c.753G>T | p.Gln251His | p.Q251H | Q9Y2G9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A3J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrazole | SD |
| SBNO2 | SNV | Missense_Mutation | novel | c.570N>T | p.Glu190Asp | p.E190D | Q9Y2G9 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SBNO2 | SNV | Missense_Mutation | c.1345G>C | p.Glu449Gln | p.E449Q | Q9Y2G9 | protein_coding | tolerated(0.3) | possibly_damaging(0.816) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SBNO2 | SNV | Missense_Mutation | novel | c.2581N>C | p.Gly861Arg | p.G861R | Q9Y2G9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A5D7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| SBNO2 | SNV | Missense_Mutation | novel | c.1190N>G | p.Ser397Cys | p.S397C | Q9Y2G9 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| SBNO2 | SNV | Missense_Mutation | novel | c.2613N>C | p.Lys871Asn | p.K871N | Q9Y2G9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| SBNO2 | deletion | Frame_Shift_Del | novel | c.1320delN | p.Glu441ArgfsTer30 | p.E441Rfs*30 | Q9Y2G9 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SBNO2 | SNV | Missense_Mutation | rs767111147 | c.2605N>A | p.Val869Met | p.V869M | Q9Y2G9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SBNO2 | SNV | Missense_Mutation | rs759888117 | c.2170N>T | p.Arg724Trp | p.R724W | Q9Y2G9 | protein_coding | deleterious(0.01) | benign(0.326) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SBNO2 | SNV | Missense_Mutation | rs200890802 | c.736N>A | p.Ala246Thr | p.A246T | Q9Y2G9 | protein_coding | tolerated(0.36) | benign(0.015) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |